Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

109.95 -0.08 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,732,775
Open 110.73
Bid (Size) 109.75 (1)
Ask (Size) 111.05 (1)
Prev. Close 110.03
Today's Range 109.77 - 111.03
52wk Range 62.07 - 111.03
Shares Outstanding 1,253,809,440
Dividend Yield 2.80%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities

Performance

YTD
+19.67%
+19.67%
1 Month
+18.17%
+18.17%
3 Month
+21.91%
+21.91%
6 Month
+43.31%
+43.31%
1 Year
+51.07%
+51.07%

More News

Read More
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
16 Analysts Have This To Say About Gilead Sciences
Via Benzinga
Why Gilead Sciences Stock Is Jumping Today
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
From Gilead Sciences, Inc.
Via Business Wire
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Via StockStory
Bullish Setups
Via Talk Markets
Topics Stocks / Equities
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Via StockStory
Top S&P500 movers in Wednesday's session
Via Chartmill
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Via Chartmill
Why Gilead Sciences (GILD) Stock Is Trading Up Today
Via StockStory
These S&P500 stocks are moving in today's session
Via Chartmill
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Discover the top S&P500 movers in Wednesday's pre-market session.
Via Chartmill
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs
Via Stocktwits
Markets Mixed On Powell Testimony, Q4 Earnings
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.